TLX vs NVS

For growth investors, Telix Pharmaceuticals Limited (TLX) is the stronger pick with 55.

8% revenue growth year-over-year, versus 6. 0% for Novartis AG (NVS). Novartis AG (NVS) offers the better valuation at 20. 3x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Telix Pharmaceuticals Limited (TLX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novartis AG (NVS) is the cheapest at 20.

3x versus Telix Pharmaceuticals Limited at 105. 7x. On forward P/E, Novartis AG is actually cheaper at 16. 7x.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +95.

1%, compared to -29. 5% for Telix Pharmaceuticals Limited (TLX). Over 10 years, the gap is even starker: NVS returned +179. 4% versus TLX's -29. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.

42β versus Telix Pharmaceuticals Limited's 0. 88β — meaning TLX is approximately 111% more volatile than NVS relative to the S&P 500. On balance sheet safety, Novartis AG (NVS) carries a lower debt/equity ratio of 80% versus 102% for Telix Pharmaceuticals Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Telix Pharmaceuticals Limited (TLX) is pulling ahead at 55.

8% versus 6. 0% for Novartis AG (NVS). On earnings-per-share growth, the picture is similar: Telix Pharmaceuticals Limited grew EPS 769. 6% year-over-year, compared to 22. 5% for Novartis AG. Over a 3-year CAGR, TLX leads at 368. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novartis AG (NVS) is the more profitable company, earning 25.

6% net margin versus 6. 4% for Telix Pharmaceuticals Limited — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus 10. 5% for TLX. At the gross margin level — before operating expenses — NVS leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Novartis AG (NVS) trades at 16.

7x forward P/E versus 167. 1x for Telix Pharmaceuticals Limited — 150. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TLX: 59. 2% to $17. 00.

In this comparison, NVS (2.

8% yield) pays a dividend. TLX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 2. 8% yield, +179. 4% 10Y return). Both have compounded well over 10 years (NVS: +179. 4%, TLX: -29. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TLX is a small-cap high-growth stock; NVS is a large-cap quality compounder stock. NVS pays a dividend while TLX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.